He found that in some cases, immune cells called ‘natural killer’ cells were active in the donor bone marrow after transplantation, and could launch an effective attack on the leukemia cells, and that he could predict in advance, using tests, how effective that would be.
In a small group of patients with acute myeloid leukemia, the survival rates improved when this kind of transplant was given with the patient already ‘in remission’ - cleared of the disease by chemotherapy.
However, it significantly increased survival - from 2percent to 30percent, among those patients whose disease had not responded fully to treatment prior to the transplant.
''For patients considered ineligible because of chemo-resistant leukemia, this is a potentially life-saving advancement. It's likely to make enormous changes in the practice of transplantation worldwide,” BBC quoted him, as saying.
The study is due to be presented at a bone marrow transplantation research conference in London.
Source-ANI
SRM/M